西地那非在儿童肺动脉高压中的应用:单中心回顾性队列研究
该单中心回顾性队列研究纳入2004至2015年接受西地那非治疗的269例肺动脉高压患儿,其中84.8%为初始单药治疗;中位随访3.1年期间,37%维持或转为他达拉非,35%因肺动脉高压改善停药,20%死亡;
要点
- 低剂量西地那非在儿童肺动脉高压中耐受性良好,安全性可接受。
- 支气管肺发育不良患儿肺动脉高压最易改善,45%可停用西地那非。
- 3组肺动脉高压患儿死亡率高,但存活者肺动脉高压改善可能性大。
核心结论
- 在以世界卫生组织1组和3组为主的儿童肺动脉高压中,低剂量西地那非耐受性良好、安全且副作用可接受。
- 3组肺动脉高压患儿死亡率高,但存活者肺动脉高压改善可能性高。
研究设计与样本
- 单中心回顾性队列研究,纳入2004至2015年接受西地那非治疗的269例肺动脉高压患儿。
- 通过病历回顾收集基线和随访数据,中位随访时间3.1年(范围2周至12.4年)。
主要发现
- 269例患儿中,特发性肺动脉高压47例,先天性心脏病53例,支气管肺发育不良135例,先天性膈疝24例,其他原因7例。
- 西地那非作为初始单药治疗占84.8%,作为添加治疗占15.2%。
- 随访期间,99例(37%)维持西地那非或转为他达拉非,93例(35%)因肺动脉高压改善停药,54例(20%)死亡,20例(7%)失访。
- 支气管肺发育不良患儿肺动脉高压最易改善,45%可停用西地那非。
临床怎么用
- 对于儿童肺动脉高压,尤其是支气管肺发育不良相关者,低剂量西地那非可作为治疗选择,且需监测气道痉挛等副作用。
- 3组肺动脉高压患儿死亡率高,应加强随访和综合管理。
局限性
- 本研究为单中心回顾性队列研究,结果可能受中心经验和患者选择偏倚影响。
- 部分患儿失访(7%),可能影响结局评估的完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the demographics, treatment algorithm, and outcomes in a large cohort of children treated with sildenafil. STUDY DESIGN: A retrospective cohort study of children with pulmonary hypertension (PH) treated with sildenafil at a single institution between 2004 and 2015. Baseline and follow-up data collected by chart review. RESULTS: There were 269 children included in this study: 47 with idiopathic pulmonary arterial hypertension, 53 with congenital heart disease, 135 with bronchopulmonary dysplasia, 24 with congenital diaphragmatic hernia, and 7 with other causes. Sildenafil was initial monotherapy in 84.8% and add-on therapy in 15.2%. Median follow-up time was 3.1 years (2 weeks-12.4 years). On follow-up, 99 (37%) remained on sildenafil or transitioned to tadalafil, 93 (35%) stopped sildenafil for improvement in PH, 54 (20%) died, and 20 (7%) were lost to follow-up. PH was most likely to improve in those with bronchopulmonary dysplasia, allowing for the discontinuation of sildenafil in 45%. Eighteen deaths were related to PH and 36 from other systemic causes. Two patients stopped sildenafil owing to airway spasm with desaturation. Overall survival was significantly lower in World Health Organization group 3 PH (bronchopulmonary dysplasia and congenital diaphragmatic hernia) vs group 1 (idiopathic pulmonary arterial hypertension and congenital heart disease), P = .02. CONCLUSIONS: In this retrospective experience in children with mainly World Health Organization groups 1 and 3 PH, low-dose sildenafil was well-tolerated, safe, and had an acceptable side effect profile. Although patients with group 3 PH have high mortality, survivors have a high likelihood of PH improving.
引用
- Cohen JL, Nees SN, Valencia GA, et al. Sildenafil Use in Children with Pulmonary Hypertension. J Pediatr. 2018. PMID: 30396684. doi:10.1016/j.jpeds.2018.09.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。